The recombinant tissue plasminogen activator (rTPA) enhances Il-8 and matrix metalalloproteinase 1 activities

The rtPA has been used extensively for cardiovascular disease to lyse preformed clots. However the dosage used (100mg) for the treatment of the myocardial infarction results cerebrovascular accidents in 9% of patients treated. The tPA therapy with much lower dosage (3 mg bid) dose for 2 weeks durati...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of allergy and clinical immunology 2004-02, Vol.113 (2), p.S214-S215
Hauptverfasser:	Hill, B.D., Nair, U., Kanangat, S., Mora, R., Barbieri, M., Yoo, T.J.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!